Paxman ABPXMBF 74 PB Ratio is 1.86 as of Jun. 25, 2026, which is 79% below its 10-year median of 8.86. GuruFocus rates PXMBF with a GF Score™ of 74/100 and a GF Value™ of $4.25. The stock has 3 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Paxman AB ranks worse than 61.04% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Paxman AB's share price is $3.50. Paxman AB's Book Value per Share for the quarter that ended in Mar. 2026 was $1.88. Hence, Paxman AB's PB Ratio of today is 1.86.
The historical rank and industry rank for Paxman AB's PB Ratio or its related term are showing as below:
PXMBF'
s PB Ratio Range Over the Past 10 Years
Min: 2.53 Med: 8.86 Max: 66.18
Current: 2.89
During the past 9 years, Paxman AB's highest PB Ratio was 66.18. The lowest was 2.53. And the median was 8.86.
PXMBF's PB Ratio is ranked worse than 61.04% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.045
vs PXMBF: 2.89
During the past 12 months, Paxman AB's average Book Value Per Share Growth Rate was 33.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 42.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 62.90% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Paxman AB was 111.70% per year. The lowest was -30.70% per year. And the median was 46.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Paxman AB PB Ratio Related Terms
Paxman AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Paxman AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Paxman AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paxman AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paxman AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Paxman AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Paxman AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Paxman AB (PXMBF) has a PB Ratio of 1.86 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Paxman AB and its competitors. This is 79% below median its historical median of 8.86. Over the past decade, Paxman AB's PB Ratio has ranged from 2.53 to 66.18. According to the industry distribution chart, Paxman AB ranks #481 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 61%.
Is Paxman AB's PB Ratio too high?
Paxman AB's current PB Ratio of 1.86 is 79% below median its 10-year median of 8.86. Over the past 10 years, this metric has ranged from a low of 2.53 to a high of 66.18. The Medical Devices & Instruments industry median PB Ratio is 2.05. Paxman AB's value of 1.86 is 9% below this industry median. Based on the distribution chart, Paxman AB ranks #481 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Paxman AB has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Paxman AB's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Paxman AB ranks #481 out of 788 companies for PB Ratio. This places Paxman AB in the lower half of its industry. The industry median PB Ratio is 2.05. Paxman AB's value of 1.86 is 9% below this benchmark. Historically, Paxman AB's own PB Ratio has ranged from 2.53 to 66.18 over the past decade. While the company's 10-year median is 8.86 vs. the industry median of 2.05, Paxman AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paxman AB's current PB Ratio of 1.86 is 9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Paxman AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paxman AB's current PB Ratio is 1.86, which is 79% below median its own 10-year median of 8.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paxman AB stock overvalued right now?
Paxman AB (PXMBF) has a current PB Ratio of 1.86. The stock's GF Value™ is $4.25, compared to a current price of $3.50 — trading 17.6% below its estimated fair value. The current PB Ratio is 1.86, which is 79% below median its 10-year median of 8.86 and 9% below the Medical Devices & Instruments industry median of 2.05. Paxman AB's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Paxman AB (PXMBF), the current PB Ratio is 1.86 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paxman AB (PXMBF) Overvalued in 2026?
Based on GuruFocus' analysis, Paxman AB stock appears to be undervalued.
The current stock price of $3.50 is trading 17.6% below its estimated GF Value™ of $4.25.
Key valuation signals for PXMBF:
PB Ratio: 1.86 (79% below median its 10-year median of 8.86)
GF Value™: $4.25 vs. price of $3.50 (17.6% below fair value)
Industry Position: 9% below the Medical Devices & Instruments median (#481 of 788)
No single metric tells the full story. See the PXMBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paxman AB is a Sweden-based company engaged in the development of the PAXMAN Scalp Cooling System, which has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The portfolio includes both the Paxman and Digni Capsystems with several installations in hospitals, clinics, and treatment centres world-wide.
74GF Score
Get the complete analysis for PXMBF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PXMBF has been successfully added to your 
